06May 2024
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial

A study examines beta-blocker use in heart failure patients with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), despite guidelines advising against it. 83% of 5,177 patients used beta-blockers, with significant regional differences. Results show beta-blocker use was associated with lower risk of adverse outcomes. Dapagliflozin, a diabetes medication, reduced risk of adverse events consistently, regardless of beta-blocker use. The study concludes beta-blockers were commonly used and didn't increase risks, and dapagliflozin was effective regardless of beta-blocker use. This suggests a potential role for beta-blockers in managing comorbidities in heart failure patients.

  • #cardiology

Like

Save

Share